{"id":1006807,"date":"2026-09-29T16:04:09","date_gmt":"2026-09-29T20:04:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/"},"modified":"2026-09-29T16:04:09","modified_gmt":"2026-09-29T20:04:09","slug":"arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/","title":{"rendered":"Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW HAVEN, Conn., Sept.  29, 2026  (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN) (\u201cArvinas\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the \u201cOption Award\u201d) and 42,388 restricted stock units (\u201cRSU\u201d) to one newly hired employee (the \u201cRSU Award\u201d). The Option Award and RSU Award were each granted as of September 28, 2026 (the \u201cGrant Date\u201d) in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas\u2019 stock incentive plan.<\/p>\n<p>The option has a 10-year term and an exercise price of $7.51 per share, which is equal to the closing price per share of Arvinas\u2019 common stock on the grant date.\u00a0The Option Award will vest over four years, with 25% of the original number of shares underlying the Option Award vesting on the one-year anniversary of the employee\u2019s start date and 1\/48th of the original number of shares vesting monthly thereafter, and the RSU Award will vest in four equal installments on each one-year anniversary of the employee\u2019s start date until the fourth anniversary of the start date, in each case subject to the employee\u2019s continued service as an employee of, or other service provider to, Arvinas through the applicable vesting dates.<\/p>\n<p>\n        <strong>About Arvinas<\/strong><br \/>\n        <br \/>Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body\u2019s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization.<\/p>\n<p>Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-393, targeting BCL6 for relapsed\/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy\u2019s disease; and ARV-6723, targeting HPK1 for advanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W124BgHbVRBzyA-v8hlQgtNwksP38UmwDHvvNgj8muHd6luJs2R97a6L9cpWscFpQk621Q9oXzocnhdD7ONRskWGyEsUb4MVvavmtI4twjTlwWD9SIJ9ONAN3UEqaik_zg6EyK7F5bzvxdvVWWFd3aOzC_TsPlWGJrrt4-Vj2MNeja-K0Ue2ZYBt4KoJARuytYOE5e5l4Z9anwOI0In0ZE5J0RvU1n5YBs0miBA3NWvpB5R_IQeLvI9IF9aFN8AP_OGtmu96Xjf2L3JCqGnZBA==\" rel=\"nofollow\" target=\"_blank\"><strong>www.arvinas.com<\/strong><\/a> and connect on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5Z6DVYgtIDzEW7chj3Ka2fIGzWY3ePm1jHYLVNl5kVL2GPgOWYHqRIkk0QJKqSg7vxDSU60sLEZDSz0_xXAXC-l3C9oFmcfHld4mltV2H7UT7Yn1A6HcXRuCccVPBsKgHHTW7l53-LZV7bXhJmRhxawtJeI4HUr762zTVaS9uHV88qp5D_OqwqVm9rG-cWVCwN9kB1M1kttNh5HAZpEATx7284P7OhYjJoQw8_PaghMjvY9q2p7TmUgvaQheoEzW\" rel=\"nofollow\" target=\"_blank\"><strong>LinkedIn<\/strong><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ON3GIEumJbOT3xqcCXcnk9SBVpziKYE23HVj2NDVZYP1CD2id52a202i0OP1t-B0VdVx1LRX5Un3v6KtrFKd232ZCdoBz0w30iMmwUpA8GLQgapY1DdYd0A4822MT3kvkyCsU1w-p1WpQZ0aOsLbq1ByIVRkKRP6YR5DyTXBquTpgrRBKOV-2zJqC__b4F_taH_72Ea6A9m_-yG9hkPEZQ==\" rel=\"nofollow\" target=\"_blank\"><strong>X<\/strong><\/a>.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Jeff Boyle<br \/>+1 (347) 247-5089<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=z_6Mxyu_DICkJp0qn_aMLsP7sSsTEfl00fwHjnXUk7s9Ldl3TxMsImpetfhlEvK77UpY4RWYRhKnzGoX9qhA4E-U387TxehgdeiUu6ENkpw=\" rel=\"nofollow\" target=\"_blank\"><strong>Jeff.Boyle@arvinas.com<\/strong><\/a><\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Kirsten Owens<br \/>+1 (203) 584-0307<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1A5fj00nX_tpVaP96luITlJA_F5-IXzIofaj1iffp4w98vrjjdC0CNe_rrgoIZ-hTpnrW5w_LoWUtK0ifpxsYgyRcmBLo7LvabbhjTz5s0XDXitL3E2OhyRUvcwF10FG\" rel=\"nofollow\" target=\"_blank\"><strong>Kirsten.Owens@arvinas.com<\/strong><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjI2MSM3ODcwMjI5IzIxMjIwNzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmIwMWYwNjQtNmExNS00OWRkLTg5YWMtZTc1NDNkMmQ0OGJiLTExMzM2NDctMjAyNi0wOS0yOS1lbg==\/tiny\/Arvinas-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN) (\u201cArvinas\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the \u201cOption Award\u201d) and 42,388 restricted stock units (\u201cRSU\u201d) to one newly hired employee (the \u201cRSU Award\u201d). The Option Award and RSU Award were each granted as of September 28, 2026 (the \u201cGrant Date\u201d) in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas\u2019 stock incentive plan. The option has a 10-year term and an exercise price of $7.51 per share, which is equal to the closing price per share of Arvinas\u2019 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1006807","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN) (\u201cArvinas\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the \u201cOption Award\u201d) and 42,388 restricted stock units (\u201cRSU\u201d) to one newly hired employee (the \u201cRSU Award\u201d). The Option Award and RSU Award were each granted as of September 28, 2026 (the \u201cGrant Date\u201d) in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas\u2019 stock incentive plan. The option has a 10-year term and an exercise price of $7.51 per share, which is equal to the closing price per share of Arvinas\u2019 &hellip; Continue reading &quot;Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-29T20:04:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjI2MSM3ODcwMjI5IzIxMjIwNzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-09-29T20:04:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/\"},\"wordCount\":452,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjI2MSM3ODcwMjI5IzIxMjIwNzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/\",\"name\":\"Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjI2MSM3ODcwMjI5IzIxMjIwNzY=\",\"datePublished\":\"2026-09-29T20:04:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjI2MSM3ODcwMjI5IzIxMjIwNzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjI2MSM3ODcwMjI5IzIxMjIwNzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/","og_locale":"en_US","og_type":"article","og_title":"Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN) (\u201cArvinas\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the \u201cOption Award\u201d) and 42,388 restricted stock units (\u201cRSU\u201d) to one newly hired employee (the \u201cRSU Award\u201d). The Option Award and RSU Award were each granted as of September 28, 2026 (the \u201cGrant Date\u201d) in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas\u2019 stock incentive plan. The option has a 10-year term and an exercise price of $7.51 per share, which is equal to the closing price per share of Arvinas\u2019 &hellip; Continue reading \"Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-29T20:04:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjI2MSM3ODcwMjI5IzIxMjIwNzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-09-29T20:04:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/"},"wordCount":452,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjI2MSM3ODcwMjI5IzIxMjIwNzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/","name":"Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjI2MSM3ODcwMjI5IzIxMjIwNzY=","datePublished":"2026-09-29T20:04:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjI2MSM3ODcwMjI5IzIxMjIwNzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjI2MSM3ODcwMjI5IzIxMjIwNzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1006807"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006807\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1006807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1006807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1006807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}